AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 804159 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin hydrochloride
Number of subjects: 244
Study 804159 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 244
Study 804159 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin
Number of subjects: 244
Study 31216196 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT
Number of subjects: 200
Study 31216196 — intervention group
Group type: COMPARATOR
Intervention: Control group (aged-matched male outpatients)
Number of subjects: 200
Study 27836205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate microbial sealant (CMS)
Number of subjects: 300
Study 27836205 — intervention group
Group type: COMPARATOR
Intervention: Standard skin preparation without CMS
Number of subjects: 300
Study 26320917 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-English speaking Hispanics
Number of subjects: 933
Study 26320917 — intervention group
Group type: EXPERIMENTAL
Intervention: English-speaking Asians
Number of subjects: 933
Study 26320917 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-English speaking Asians
Number of subjects: 933
Study 22956434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (TAC) plus prednisone for 12 months
Number of subjects: 56
Study 22956434 — intervention group
Group type: COMPARATOR
Intervention: Prednisone combined with intravenous cyclophosphamide (CYC) for 24 weeks
Number of subjects: 56
Study 22956434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (TAC) plus prednisone
Number of subjects: 56
Study 22111446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 41
Study 22111446 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/Fentanyl
Number of subjects: 41
Study 19700774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral enoximone
Number of subjects: 1854
Study 19700774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1854
Study 17145722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 19257
Study 17145722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily (Amlodipine-based regimen)
Number of subjects: 19257
Study 17145722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily (Atenolol-based regimen)
Number of subjects: 19257
Study 17145722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Amlodipine-based regimen)
Number of subjects: 19257
Study 17145722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Atenolol-based regimen)
Number of subjects: 19257
Study 15307550 — intervention group
Group type: EXPERIMENTAL
Intervention: PMEA coated circuit and oxygenator (group X)
Number of subjects: 30
Study 15307550 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin coated circuit and oxygenator (group H)
Number of subjects: 30
Study 15307550 — intervention group
Group type: COMPARATOR
Intervention: Noncoated circuit and oxygenator (group N)
Number of subjects: 30
Study 11148715 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 11148715 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 0
Study 9060560 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) filgrastim; 5 microg/kg/d
Number of subjects: 186
Study 9060560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 8405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection into the thigh (IMT)
Number of subjects: 55
Study 8405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection into the abdominal wall (SCA)
Number of subjects: 55
Study 8405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection into the thigh (SCT)
Number of subjects: 55
Study 8405743 — intervention group
Group type: COMPARATOR
Intervention: Control group (SCA and IMT)
Number of subjects: 55
Study 3776949 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ethanol (6 ml)
Number of subjects: 10
Study 3776949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% ethanol)
Number of subjects: 10
Study 3776949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (20 mg/kg iv)
Number of subjects: 10
Study 30354975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Baclofen (ITB)
Number of subjects: 60
Study 30354975 — intervention group
Group type: COMPARATOR
Intervention: Conventional Medical Management (CMM)
Number of subjects: 60
Study 27049100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal T-LysYal
Number of subjects: 89
Study 27049100 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 89
Study 24642785 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium (CAL) supplementation (1400 mg of calcium)
Number of subjects: 13
Study 24642785 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) supplementation (400 mg of calcium)
Number of subjects: 13
Study 22638306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-sponsored bags with no formula at source (intervention group)
Number of subjects: 527
Study 22638306 — intervention group
Group type: COMPARATOR
Intervention: Industry-sponsored formula sample packs (control group)
Number of subjects: 527
Study 20516658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene (30 mg/day)
Number of subjects: 30
Study 20516658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose beta-carotene (90 mg/day)
Number of subjects: 30
Study 20516658 — intervention group
Group type: COMPARATOR
Intervention: Baseline (control)
Number of subjects: 30
Study 18541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol ointment
Number of subjects: 12
Study 18541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol lotion
Number of subjects: 12
Study 15825531 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD ophthalmic solution (0.5% tropicamide, 0.5% phenylephrine, 0.1% diclofenac)
Number of subjects: 38
Study 15825531 — intervention group
Group type: COMPARATOR
Intervention: Individual solutions (0.5% tropicamide/0.5% phenylephrine, 5% phenylephrine, 0.1% diclofenac)
Number of subjects: 38
Study 15825531 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD ophthalmic solution
Number of subjects: 38
Study 12806380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyrus bipolar electrovaporization
Number of subjects: 0
Study 12806380 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 12806380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyrus bipolar electrovaporization and TURP
Number of subjects: 0
Study 12577372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium polyglucoside (TII)
Number of subjects: 30
Study 12577372 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 30
Study 12577372 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 30
Study 9463561 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalative beclomethasone
Number of subjects: 57
Study 9463561 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (10 mg per day)
Number of subjects: 57
Study 7944840 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate medication use
Number of subjects: 414
Study 7944840 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects using three or more prescription drugs
Number of subjects: 414
Study 7944840 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with depressive symptoms
Number of subjects: 414
Study 3295625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) at 1.2 X 10(6) IU/m2 for 28 days, subcutaneously (s.c.)
Number of subjects: 97
Study 3295625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose treatment of Hr IFn-2c at 1.2 X 10(5) IU/m2, s.c. daily increasing to a well-tolerated dose
Number of subjects: 97
Study 31777234 — intervention group
Group type: EXPERIMENTAL
Intervention: Buqi Yixue needling
Number of subjects: 86
Study 31777234 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol (50 mg/time, 2 times/d) and Epalrestat (50 mg/time, 3 times/d)
Number of subjects: 86
Study 29121625 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face delivery of the Green Prescription
Number of subjects: 138
Study 25131892 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance directive and proxy opinion available and concordant
Number of subjects: 0
Study 25131892 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance directive opposed, proxy favored intervention
Number of subjects: 0
Study 25131892 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance directive favored intervention, proxy opposed
Number of subjects: 0
Study 25131892 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance between instructions
Number of subjects: 0
Study 25131892 — intervention group
Group type: COMPARATOR
Intervention: No instruction (control)
Number of subjects: 0
Study 22209741 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index (GI) diet
Number of subjects: 511
Study 22209741 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load (GL) diet
Number of subjects: 511
Study 22209741 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic index (GI) diet
Number of subjects: 511
Study 22209741 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic load (GL) diet
Number of subjects: 511
Study 22152723 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously at 8-week intervals
Number of subjects: 35
Study 20297714 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam plus ketamine (MK)
Number of subjects: 36
Study 20297714 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine plus ketamine (PK)
Number of subjects: 36
Study 20297714 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam plus tramadol (MT)
Number of subjects: 36
Study 20297714 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine plus tramadol (PT)
Number of subjects: 36
Study 16502769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril test formulation from Laboratórios Biosintética Ltda (5 mg)
Number of subjects: 26
Study 16502769 — intervention group
Group type: COMPARATOR
Intervention: Triatec formulation from Aventis Pharma (5 mg)
Number of subjects: 26
Study 15208585 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol metered‐dose inhalers (16 cumulative puffs, doubled at 15-minute intervals)
Number of subjects: 15
Study 11085051 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + K (TTS natural estrogens 50 micrograms/day with progestin and Kava‐Kava extract at a dose of 100 mg, n=13)
Number of subjects: 40
Study 11085051 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT + K (TTS natural estrogens 50 micrograms/day and Kava‐Kava extract at a dose of 100 mg, n=11)
Number of subjects: 40
Study 11085051 — intervention group
Group type: COMPARATOR
Intervention: HRT (TTS natural estrogens 50 micrograms/day with progestin and a placebo product, n=9)
Number of subjects: 40
Study 11085051 — intervention group
Group type: COMPARATOR
Intervention: ERT (TTS natural estrogens 50 micrograms/day and a placebo product, n=7)
Number of subjects: 40
Study 9330431 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus levels allocated using a randomized design based on a generalized Polya urn model.
Number of subjects: 0
Study 9330431 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimodal and symmetric allocation of stimulus levels around the unknown median of the stimulus-response curve.
Number of subjects: 0
Study 9330431 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical studies conducted in neurophysiology in humans.
Number of subjects: 0
Study 7689778 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of alkylating agents
Number of subjects: 35
Study 7689778 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 35
Study 7689778 — intervention group
Group type: COMPARATOR
Intervention: Intensified protocols supported by hematopoietic growth factors
Number of subjects: 35
Study 31649304 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (315 μg/kg PO)
Number of subjects: 39
Study 31649304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28541926 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + omega-3 PUFA 2.52 g/day
Number of subjects: 105
Study 28541926 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + omega-3 PUFA 2.52 g/day + CoQ10 200 mg/day
Number of subjects: 105
Study 28541926 — intervention group
Group type: COMPARATOR
Intervention: Control group (unaltered statin therapy)
Number of subjects: 105
Study 25407083 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibroblast-derived dermal substitute plus standard wound care
Number of subjects: 314
Study 25407083 — intervention group
Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 314
Study 24348043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E tocotrienol-rich fraction (TRF) 180 mg tocotrienols, 40 mg tocopherols
Number of subjects: 81
Study 24348043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.48 mg tocotrienols, 0.88 mg tocopherols)
Number of subjects: 81
Study 21513530 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention programme including weekly lifestyle-lessons for children, teacher training, and parent training.
Number of subjects: 15
Study 21513530 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention programme
Number of subjects: 15
Study 18840702 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to disability and hearing loss narratives
Number of subjects: 35
Study 18840702 — intervention group
Group type: COMPARATOR
Intervention: No exposure to disability and hearing loss narratives
Number of subjects: 35
Study 16942618 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan/HCTZ (16 mg/12.5 mg) with passive compliance monitoring (Group B)
Number of subjects: 62
Study 16942618 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan/HCTZ (16 mg/12.5 mg) with DRC intervention program (Group C)
Number of subjects: 62
Study 16942618 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (Group A)
Number of subjects: 62
Study 12946764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoplasty with cecum and ascending colon (Group 1)
Number of subjects: 28
Study 12946764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoid cystoplasty (Group 2)
Number of subjects: 28
Study 10861338 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine (L-C) 2 g twice daily for 8 weeks
Number of subjects: 36
Study 10861338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose) 2 g twice daily for 8 weeks
Number of subjects: 36
Study 9182742 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 25% tetracycline fibers (S&T)
Number of subjects: 54
Study 9182742 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 2% minocycline gel (S&Mi)
Number of subjects: 54
Study 9182742 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 25% metronidazole gel (S&Me)
Number of subjects: 54
Study 9182742 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (S)
Number of subjects: 54
Study 8237295 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP
Number of subjects: 11
Study 8237295 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 cm H2O PEEP
Number of subjects: 11
Study 8237295 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm H2O PEEP
Number of subjects: 11
Study 8237295 — intervention group
Group type: COMPARATOR
Intervention: 0 cm H2O PEEP (baseline)
Number of subjects: 11
Study 2422004 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (synthetic ACTH4-9 analog), 40 mg daily for 6 months
Number of subjects: 77
Study 2422004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 2422004 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (synthetic ACTH4-9 analog)
Number of subjects: 77
Study 30212849 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-optimized treatment (A-OT): 3 weeks of prequit mini-lozenges, 26 weeks of nicotine patch + mini-lozenges, three in-person and eight phone counseling sessions, and 7-11 automated calls to prompt medication use
Number of subjects: 623
Study 30212849 — intervention group
Group type: COMPARATOR
Intervention: Recommended usual care (R-UC): 10 min of in-person counseling, 8 weeks of nicotine patch, and referral to quitline services
Number of subjects: 623
Study 27958384 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol injection (n=10)
Number of subjects: 26
Study 27958384 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided iodine-125 seed implantation (n=13)
Number of subjects: 26
Study 27958384 — intervention group
Group type: EXPERIMENTAL
Intervention: Second EUS-guided intervention (n=5)
Number of subjects: 26
Study 27958384 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (n=1)
Number of subjects: 26
Study 27958384 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (n=2)
Number of subjects: 26
Study 23856100 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day of oral olanzapine
Number of subjects: 44
Study 23856100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 22800696 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao capsules (2 g/d) for 28 days after operation
Number of subjects: 200
Study 22800696 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (2 g/d) for 28 days after operation
Number of subjects: 200
Study 20367775 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (target blood alcohol level = 0.10%)
Number of subjects: 0
Study 20367775 — intervention group
Group type: COMPARATOR
Intervention: Control condition (sober women)
Number of subjects: 0
Study 20367775 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sexual arousal
Number of subjects: 0
Study 17928026 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on identifying crowded letters
Number of subjects: 0
Study 15173694 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri‐procedural hemofiltration
Number of subjects: 114
Study 15173694 — intervention group
Group type: COMPARATOR
Intervention: Saline hydration
Number of subjects: 114
Study 11719594 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-G*0104 or HLA-G*0105N allele presence
Number of subjects: 113
Study 9131355 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach to skillful, safe, and appropriate use of touch synthesized with an awareness of the breath
Number of subjects: 0
Study 7957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol at 100 micrograms.kg‐1 BW.min‐1
Number of subjects: 0
Study 7957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol at 250 micrograms.kg‐1 BW.min‐1
Number of subjects: 0
Study 7957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol at 500 micrograms.kg‐1 BW.min‐1
Number of subjects: 0
Study 7957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (all doses)
Number of subjects: 0
Study 7957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms.kg‐1 BW.min‐1)
Number of subjects: 0
Study 3300711 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative CMF chemotherapy
Number of subjects: 1022
Study 3300711 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative tamoxifen
Number of subjects: 1022
Study 3300711 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (Control)
Number of subjects: 1022
Study 3300711 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiation therapy (Control)
Number of subjects: 1022
Study 29098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap group
Number of subjects: 160
Study 29098255 — intervention group
Group type: COMPARATOR
Intervention: Flapless group
Number of subjects: 160
Study 29098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 27288803 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 87
Study 27288803 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 87
Study 27288803 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 87
Study 24914427 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 186
Study 24914427 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 186
Study 22473347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ppm ozonated water
Number of subjects: 0
Study 22473347 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 0
Study 19325497 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex extended-release (ER)
Number of subjects: 150
Study 19325497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19325497 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term study
Number of subjects: 150
Study 17470670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal auto-titrating CPAP
Number of subjects: 26
Study 17470670 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 26
Study 16130876 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (DW) without sealer
Number of subjects: 72
Study 16130876 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water (DW) + AH Plus
Number of subjects: 72
Study 16130876 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water (DW) + Endofill
Number of subjects: 72
Study 16130876 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl without sealer
Number of subjects: 72
Study 16130876 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + AH Plus
Number of subjects: 72
Study 16130876 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + Endofill
Number of subjects: 72
Study 12029205 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 58